Clinical trial
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in…
NCT00157079 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00157079 |
|---|---|
| Title | Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders |
| Official title | A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome |
| Intervention type | Biological |
| Interventions | Immune Globulin Intravenous (Human), 10% |
| Enrollment | 61 |
| Start date | Jun 25, 2002 |
| Primary completion | Dec 16, 2003 |
| Completion | Dec 16, 2003 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 24, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: